ETF / Index • Equal-Weight Clinical Biotech • SIC 6726
$152.05 ▼ -1.81
(-1.16%)
MKT CAP: $7.40B • VOL: 9.08M
52W L $106 52W H $170
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$128
MEDIAN
$170
MEAN
$173
HIGH
$207
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE XBI TAPE
XBI // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $183.98 | $174.86 | 2025-02-14 | $138.37 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $191.58 | $179.42 | 2025-02-06 | $142.93 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $173.34 | $167.26 | 2025-01-29 | $145.97 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $155.09 | — | 2025-01-17 | $149.01 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $133.80 | $144.45 | 2025-01-09 | $135.32 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $180.94 | $158.13 | 2024-12-18 | $132.28 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $147.49 | $153.57 | 2024-12-04 | $141.41 | -4.3% | 48% | C |